Novel oral SPT inhibitor CH5169356 inhibits hepatic stellate cell activation and ameliorates hepatic fibrosis in mouse models of non‐alcoholic steatohepatitis (NASH)

• Hauptverfasser: Natsuko Hada (Verfasst von), Asao Katsume (Verfasst von), Kawasaki Kenichi (Verfasst von), Chihiro Endo (Verfasst von), Naoshi Horiba (Verfasst von), Masayuki Sudoh (Verfasst von)
• Format: Buch
• Veröffentlicht: Wiley, 2023-06-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Abstract Ceramide is a central molecule of sphingolipid metabolism and is involved in the development of non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH). It has already been reported that the inhibition of serine palmitoyltransferase (SPT), the rate‐limiting enzyme...